Hair loss treatment

Posts

August Is National Hair Loss Awareness Month

August Is National Hair Loss Awareness Month

August Is National Hair Loss Awareness Month

According to the American Hair Loss Association (AHLA), an estimated 50 million men experience some level of hair loss and approximately 35 million women are also affected by thinning hair. To help those who are suffering from this condition, National Hair Loss Awareness Month (NHLAM) delivers attention to detection, prevention, and treatment of these unfortunate yet oftentimes reversible statistics.

Dr. Alan J. Bauman Reveals Bulletproof Founder Dave Asprey’s “Upgraded Hair” After His Bulletproof Radio Podcast on Biohacking Baldness

World-Renowned Hair Restoration Surgeon Dr Alan J Bauman Announces New Technologies to Detect Prevent Treat Hair Loss

The medical community also continues to see a correlation between COVID-19 and hair loss. The past 18 months have delivered unimaginable stressors and challenges. Excessive or prolonged psychological and physiological stress including fever-related illnesses can trigger heavy shedding (telogen effluvium) and accelerate hair loss.

Even those not physically infected with COVID can experience the detrimental effects of the Pandemic on their hair, scalp, and other organs. More than a quarter of patients recovering from COVID-19 have reported hair loss as one of the lingering problems from the illness.

Internationally recognized, ABHRS-Certified Hair Restoration Surgeon Dr Alan J. Bauman discusses the most efficient and effective protocols of hair loss prevention and highlights some of the newest technology in the field of hair restoration aimed at both preserving and restoring the hair.

According to Dr Bauman, who was recently named “Top Hair Restoration Surgeon of the Decade” by Aesthetic Everything®, “Early action is essential to improving the fate of the follicle. While most hair loss may be hereditary,” he states “with proper intervention, it’s also avoidable.” Because early detection and precise analysis are key to identifying the most accurate source of treatment, experts in hair restoration are celebrating the advancements in the science of hair loss detection.

ADVANCEMENTS IN DETECTION & TREATMENT

Trichotest® Genetic Hair Loss Testing performs genetic testing based on state-of-the-art DNA microarray technology to identify the exact hair loss treatments that will perform best for the patient based on DNA analysis. Trichotest® examines DNA from saliva together with details about the patients’ lifestyle and then analyzes a total of 48 genetic variations to understand specific characteristics of the metabolism which contribute to hair loss. Using proven scientifically validated global research, Trichotest® enables hair restoration experts to recommend the most successful treatment option.

HairMetrix® is the first Artificial Intelligence (AI) driven non-invasive hair measurement tool for consultations. Based on a machine-learning algorithm, the HairMetrix® system provides real-time analysis of hair density, hair calibre, and other metrics that contribute vital information to a Hair Restoration Physician and his patient by first establishing a baseline in more permanent areas of hair growth, and then comparing those measurements to weaker zones. HairMetrix® also allows for the precise tracking of hair growth results over time. Dr Bauman is one of the first physicians worldwide to use this new AI hair analysis system.

TREATING HAIR AT HOME

After a virtual or in-person consultation, at-home treatment programs include premium prescribed products such as specially formulated non-greasy highly-rated Minoxidil Formula 82M, to Formula 82F Topical Finasteride+Minoxidil and Formula 82D Topical Dutasteride+Minoxidil to the powerful FDA-cleared Bauman TURBO LaserCap Low-Level Laser Therapy device for hair regrowth, to bespoke Nutritional Supplements, and DHT-Control hair care products.

IN-OFFICE REGENERATIVE TREATMENTS

If at-home treatments don’t suffice, there are a plethora of in-office regenerative medicine treatments including PRP Platelet Rich Plasma, PDOgro™, Exosome Therapy, and other cell therapy interventions.

HAIR TRANSPLANTS

If an assessment confirms that hair follicles are dead and gone, a transplant is needed. Today’s state-of-the-art hair transplant technology includes the no-linear-scar, minimally-invasive FUE hair transplant surgery as well as the No-Shave Long-Hair Preview VIP|FUE™, a groundbreaking, minimally invasive hair transplant procedure. VIP|FUE™ delivers all the hair restoration benefits of traditional FUE without any shaving or trimming of hair.

Dr Bauman recently revealed Bulletproof Founder Dave Asprey’s “upgraded hair” at Asprey’s Virtual Biohacking Conference. Asprey, considered the “Father of Biohacking”, was at Bauman Medical last year for a 4,087 graft FUE hair transplant procedure, which also included PRP Platelet Rich Plasma with Extracellular Matrix, and followed up with at-home hair regrowth treatments using Dr Bauman’s FDA-cleared TURBO LaserCap. Asprey’s keen social media followers had already noticed “something different” about his hair and were amazed at his results. Dr Bauman will be a featured presenter discussing “Biohacking Baldness” at the upcoming in-person Upgrade 7th Annual Biohacking Conference in Orlando September 17-19.

To learn more about the newest advancements in hair restoration, please visit www.baumanmedical.com. For media interviews, please contact danna@canpublicity.com

About Alan J. Bauman, MD, ABHRS

Alan J. Bauman, MD, ABHRS is a full-time board-certified Hair Restoration Physician who has treated nearly 30,000 patients and performed over 10,000 hair transplant procedures since starting his medical hair loss practise, Bauman Medical, in 1997 in Boca Raton, FL.

Dr Bauman is one of approximately only 200 physicians worldwide to achieve certification from the esteemed American Board of Hair Restoration Surgery (ABHRS), become an accepted member of the International Alliance of Hair Restoration Surgeons (IAHRS), and also be recommended by the American Hair Loss Association. Dr Bauman has achieved the coveted Fellow status within the International Society of Hair Restoration Surgery (ISHRS), is a frequently invited faculty member at numerous international scientific meetings and live surgery workshops, and has published numerous articles and textbook chapters in the field of hair restoration and hair transplantation.

Dr Bauman has consistently been shortlisted for numerous Top Hair Transplant Surgeon recognitions and awards worldwide. He has been named “#1 Top Hair Restoration Surgeon” in North America by Aesthetic Everything for five years running and recently named by Forbes as one of “Ten CEOs Transforming Healthcare in America.” As a respected global expert in hair loss and hair restoration and a pioneer of many techniques, technologies and devices in the field, he has appeared in hundreds of feature stories and live interviews in the mass media and top health podcasts. In addition to lecturing and consulting worldwide, Dr Bauman sees patients personally and operates in his nearly 12,000 square foot “Hair Hospital” in downtown Boca Raton, FL.

August Is National Hair Loss Awareness Month

Source

Recent Posts

August Is National Hair Loss Awareness Month

August Is National Hair Loss Awareness Month

August Is National Hair Loss Awareness Month

According to the American Hair Loss Association (AHLA), an estimated 50 million men experience some level of hair loss and approximately 35 million women are also affected by thinning hair. To help those who are suffering from this condition, National Hair Loss Awareness Month (NHLAM) delivers attention to detection, prevention, and treatment of these unfortunate yet oftentimes reversible statistics.

Dr. Alan J. Bauman Reveals Bulletproof Founder Dave Asprey’s “Upgraded Hair” After His Bulletproof Radio Podcast on Biohacking Baldness

World-Renowned Hair Restoration Surgeon Dr Alan J Bauman Announces New Technologies to Detect Prevent Treat Hair Loss

The medical community also continues to see a correlation between COVID-19 and hair loss. The past 18 months have delivered unimaginable stressors and challenges. Excessive or prolonged psychological and physiological stress including fever-related illnesses can trigger heavy shedding (telogen effluvium) and accelerate hair loss.

Even those not physically infected with COVID can experience the detrimental effects of the Pandemic on their hair, scalp, and other organs. More than a quarter of patients recovering from COVID-19 have reported hair loss as one of the lingering problems from the illness.

Internationally recognized, ABHRS-Certified Hair Restoration Surgeon Dr Alan J. Bauman discusses the most efficient and effective protocols of hair loss prevention and highlights some of the newest technology in the field of hair restoration aimed at both preserving and restoring the hair.

According to Dr Bauman, who was recently named “Top Hair Restoration Surgeon of the Decade” by Aesthetic Everything®, “Early action is essential to improving the fate of the follicle. While most hair loss may be hereditary,” he states “with proper intervention, it’s also avoidable.” Because early detection and precise analysis are key to identifying the most accurate source of treatment, experts in hair restoration are celebrating the advancements in the science of hair loss detection.

ADVANCEMENTS IN DETECTION & TREATMENT

Trichotest® Genetic Hair Loss Testing performs genetic testing based on state-of-the-art DNA microarray technology to identify the exact hair loss treatments that will perform best for the patient based on DNA analysis. Trichotest® examines DNA from saliva together with details about the patients’ lifestyle and then analyzes a total of 48 genetic variations to understand specific characteristics of the metabolism which contribute to hair loss. Using proven scientifically validated global research, Trichotest® enables hair restoration experts to recommend the most successful treatment option.

HairMetrix® is the first Artificial Intelligence (AI) driven non-invasive hair measurement tool for consultations. Based on a machine-learning algorithm, the HairMetrix® system provides real-time analysis of hair density, hair calibre, and other metrics that contribute vital information to a Hair Restoration Physician and his patient by first establishing a baseline in more permanent areas of hair growth, and then comparing those measurements to weaker zones. HairMetrix® also allows for the precise tracking of hair growth results over time. Dr Bauman is one of the first physicians worldwide to use this new AI hair analysis system.

TREATING HAIR AT HOME

After a virtual or in-person consultation, at-home treatment programs include premium prescribed products such as specially formulated non-greasy highly-rated Minoxidil Formula 82M, to Formula 82F Topical Finasteride+Minoxidil and Formula 82D Topical Dutasteride+Minoxidil to the powerful FDA-cleared Bauman TURBO LaserCap Low-Level Laser Therapy device for hair regrowth, to bespoke Nutritional Supplements, and DHT-Control hair care products.

IN-OFFICE REGENERATIVE TREATMENTS

If at-home treatments don’t suffice, there are a plethora of in-office regenerative medicine treatments including PRP Platelet Rich Plasma, PDOgro™, Exosome Therapy, and other cell therapy interventions.

HAIR TRANSPLANTS

If an assessment confirms that hair follicles are dead and gone, a transplant is needed. Today’s state-of-the-art hair transplant technology includes the no-linear-scar, minimally-invasive FUE hair transplant surgery as well as the No-Shave Long-Hair Preview VIP|FUE™, a groundbreaking, minimally invasive hair transplant procedure. VIP|FUE™ delivers all the hair restoration benefits of traditional FUE without any shaving or trimming of hair.

Dr Bauman recently revealed Bulletproof Founder Dave Asprey’s “upgraded hair” at Asprey’s Virtual Biohacking Conference. Asprey, considered the “Father of Biohacking”, was at Bauman Medical last year for a 4,087 graft FUE hair transplant procedure, which also included PRP Platelet Rich Plasma with Extracellular Matrix, and followed up with at-home hair regrowth treatments using Dr Bauman’s FDA-cleared TURBO LaserCap. Asprey’s keen social media followers had already noticed “something different” about his hair and were amazed at his results. Dr Bauman will be a featured presenter discussing “Biohacking Baldness” at the upcoming in-person Upgrade 7th Annual Biohacking Conference in Orlando September 17-19.

To learn more about the newest advancements in hair restoration, please visit www.baumanmedical.com. For media interviews, please contact danna@canpublicity.com

About Alan J. Bauman, MD, ABHRS

Alan J. Bauman, MD, ABHRS is a full-time board-certified Hair Restoration Physician who has treated nearly 30,000 patients and performed over 10,000 hair transplant procedures since starting his medical hair loss practise, Bauman Medical, in 1997 in Boca Raton, FL.

Dr Bauman is one of approximately only 200 physicians worldwide to achieve certification from the esteemed American Board of Hair Restoration Surgery (ABHRS), become an accepted member of the International Alliance of Hair Restoration Surgeons (IAHRS), and also be recommended by the American Hair Loss Association. Dr Bauman has achieved the coveted Fellow status within the International Society of Hair Restoration Surgery (ISHRS), is a frequently invited faculty member at numerous international scientific meetings and live surgery workshops, and has published numerous articles and textbook chapters in the field of hair restoration and hair transplantation.

Dr Bauman has consistently been shortlisted for numerous Top Hair Transplant Surgeon recognitions and awards worldwide. He has been named “#1 Top Hair Restoration Surgeon” in North America by Aesthetic Everything for five years running and recently named by Forbes as one of “Ten CEOs Transforming Healthcare in America.” As a respected global expert in hair loss and hair restoration and a pioneer of many techniques, technologies and devices in the field, he has appeared in hundreds of feature stories and live interviews in the mass media and top health podcasts. In addition to lecturing and consulting worldwide, Dr Bauman sees patients personally and operates in his nearly 12,000 square foot “Hair Hospital” in downtown Boca Raton, FL.

August Is National Hair Loss Awareness Month

Source

Recent Posts

Global Anti-dandruff

Global Anti-dandruff

Global Anti-dandruff Agent Additive Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026

The Anti-dandruff Agent Additive market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, the impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Anti-dandruff Agent Additive size is estimated to be xx million in 2021 from USD xx million in 2020, with a change of XX% between 2020 and 2021. The global Anti-dandruff Agent Additive market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation

Anti-dandruff Agent Additive market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

Piroctone Olamine

Climbazole

Slaicylic Acid

Ketoconazole

Coal Tar

Selenium Sulfide

Other

Market segment by Application can be divided into

Personal Care

Pharmaceutical

The key market players for global Anti-dandruff Agent Additive market are listed below:

Clariant AG

Aurora Chemical

Spec Chem Group

Kumar Organic

Chemspec Chemicals

3C Pharmchem

Somu Group

Kolon Life Science

Regen Chemical

Symrise

Tinci Materials

Seqens SAS

Merck KGaA

Plater Group

Gaopeng Pharmaceutical

Kavya Pharma

Fengchen Technology

Xi’an Taicheng Chem

Market segment by Region, regional analysis covers

North America (the United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of the Middle East & Africa)

The content of the study subjects includes a total of 14 chapters:

Chapter 1, describe Anti-dandruff Agent Additive product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Anti-dandruff Agent Additive, with price, sales, revenue and global market share of Anti-dandruff Agent Additive from 2019 to 2021.

Chapter 3, the Anti-dandruff Agent Additive competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Anti-dandruff Agent Additive breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2016 to 2026.

Chapters 5 and 6, segment the sales by type and application, with sales market share and growth rate by type, application, from 2016 to 2026.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2016 to 2021.and Anti-dandruff Agent Additive market forecast, by regions, type and application, with sales and revenue, from 2021 to 2026.

Chapters 12, 13 and 14, describe Anti-dandruff Agent Additive sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Global Anti-dandruff Agent Additive Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026

Source

Recent Posts

Minimally Invasive Hair Restoration Course

Minimally Invasive Hair Restoration Course

Anthony Bared MD, FACS to Teach Minimally Invasive Hair Restoration Course at Upcoming Miami Cosmetic Surgery Conference

One of Miami’s most accomplished facial plastic surgeons and hair restoration experts, Dr Anthony Bared, M.D., F.A.C.S., will be sharing his knowledge at the August MCS conference on the most effective hair restoration techniques and how cosmetics surgeons can begin to offer these procedures.

Dr Bared’s speciality course, Hair Restoration in Aesthetics, will take place on Saturday, August 28, 2021, between 8:15-9:45 AM in the America/Chicago rooms of the conference venue, the Miami Beach Convention Center.

The Miami Cosmetic Surgery (MCS) conference is considered a leading industry event where specialists, renowned researchers, educators, and practitioners convene to share and discuss cutting edge knowledge regarding advancements in cosmetic surgery. Dr Bared’s workshop is part of the overall conference which takes place from August 25-28th.

Dr Bared works alongside Dr Jeffrey Epstein at the Foundation for Hair Restoration for Plastic Surgery where he performs surgical and non-invasive procedures for the management of hair loss. At the MCS conference, Dr Bared will discuss the growing demand for hair loss treatments for men and women of all ages and the effective minimally invasive procedures cosmetic surgeons can incorporate into their practices to address and improve patient outcomes.

These include threads for hair restoration, various device-based and energy-based options, platelet-rich plasma (PRP), as well as topical and nutraceutical therapies. Course attendees will gain insights on effectively and efficiently incorporating these services into their aesthetic practices, resulting in new patients and high patient satisfaction.

“With the latest advancements in treatments for hair loss, there are many effective options that practitioners can quickly adapt as options for their current and prospective patients who are suffering from hair loss,” said Dr. Bared. “I regularly treat patients with these procedures, depending on the type and extent of hair loss that they are presenting with, and have seen positive results achieved with time and repeated treatments.”

He continued, “The extent to which these therapies affect patients suffering from hair loss should not be understated. They can make a marked improvement in patient confidence as well as add significant revenue streams to aesthetic practices.”

To learn more about Dr. Bared and the full suite of surgical and non-surgical procedures he performs, visit http://www.facialplasticsurgerymiami.com.

To learn more about the Miami Cosmetic Surgery conference and to register to attend, visit http://www.miamicosmeticsurgery.info/.

About Dr Anthony Bared

Dr Anthony Bared, M.D., F.A.C.S., is “Miami’s Facial Plastic Surgeon.” With training in Otolaryngology at the University of Miami followed by one of only forty spots for a highly competitive fellowship by the American Academy of Facial Plastic and Reconstructive Surgery at the University of Illinois – Chicago, Dr Bared is a celebrated double board-certified facial plastic surgeon.

He has authored numerous scientific articles and given lectures nationwide on various cosmetic specialities. As a talented and compassionate surgeon, Dr Bared provides rhinoplasty, injectables, hair loss management and more. Anthony Bared MD, FACS to Teach Minimally Invasive Hair Restoration Course at Upcoming Miami Cosmetic Surgery Conference

Source

Recent Posts

Hair Transplant Before and After Photos

Clinic for Female Hair Transplant

Silicon Valley Institute, Best Class Clinic for Female Hair Transplant, Announces New ‘Before and After’ Page for Women

Silicon Valley Hair Institute, a highly-rated Bay Area hair transplantation clinic is proud to announce a new page focused on women’s hair loss treatments. The newly released before-and-after photos of women’s hair restoration including hairline treatments are available to review.

“Women’s hair loss is not the same as men’s. We believe a page centred around their experiences may be helpful to the community,” explained Miguel Canales, MD. “Photos show our female patients before and after their hair loss treatments so the public can see the results for themselves.”

The public can review the new “before and after” page focused on female hairline restoration. Silicon Valley Institute, Best Class Clinic for Female Hair Transplant, Announces New ‘Before and After’ Page for Women Thinner, more brittle hair could be signs of female hair loss instead of a typical “receding” hairline found in men. A top clinic focused on female hair transplant support in the Bay Area can help residents review options.

Treatments for women can include the following: robotic hair transplant surgery, light therapy, and supplement protocols. The clinic serves both women and men prepared to address hair loss issues. Bay Area residents can review the clinic’s “before and after” page for men at https://siliconvalleyhairinstitute.com/before-after/.

Those looking for skincare issues are encouraged to visit the sister website at https://svaestheticderm.com/.

FEMALE HAIR TRANSPLANT CLINIC IN BAY AREA AIMS THE SPOTLIGHT ON WOMEN’S HAIR LOSS

Here is the background on this release. Baldness may be a common issue for men living in the San Francisco area. However, women struggling with thinning hair confront unique problems. Confusion over how to manage the problem and a loss of confidence could result from thinning hair in women.

For these reasons, Silicon Valley Hair Institute announces a new women-centred page of “before and after” examples of hair loss treatments, especially for hair line issues. Female hair loss can present as a widening part and all-over thinner hair. Treatments may include hair transplantation, nutritional protocols, and micro-pigmentation. A state-of-the-art clinic helps focus the spotlight on female hair transplant services in the Bay Area.

ABOUT THE SILICON VALLEY HAIR INSTITUTE

Silicon Valley Hair Institute under the leadership of top-rated California hair transplant surgeon Dr Miguel Canales – is one of the best robotic hair transplant clinics in the San Francisco Bay Area.

Dr Canales provides both the FUT (Follicular Unit Transplant and FUE hair transplant (Follicular Unit Extraction procedures.

Dr Canales is a top-rated hair transplant specialist for Bay Area residents. The Silicon Valley Hair Institute specializes in hair loss and hair restoration needs in San Francisco, San Jose, and the Silicon Valley Peninsula (Sunnyvale, Mountain View, Palo Alto, Los Altos, Menlo-Atherton, Redwood City, and beyond.). Dr Canales also specializes in aesthetic hair restoration for females seeking eyebrow transplantation or hairline advancements.

Silicon Valley Institute, Best Class Clinic for Female Hair Transplant, Announces New ‘Before and After’ Page for Women

Source

Recent Posts

Hair Loss Men and Women

Hair Loss Men and Women

Hair Loss Men and Women Comprehensive Study

Hair loss in men and women experience androgenetic alopecia with equal frequency, although it may be camouflaged better in women. The other terms for androgenetic alopecia such as “male pattern balding” and “female pattern hair loss”.

According to the American Hair Loss Association, approximately two-thirds of men will have lost a little hair by the age of thirty-five and approximately 85% of men and women will have experienced hair thinning or have lost a significant amount of hair by the age of fifty.

Growth Drivers

  • Increasing Hair Loss Problems
  • Increased geriatric population in the developed economies
  • Rising Disposable Income

Market Trends

  • Rising consumer concern pertaining to receding hairlines

Roadblocks

  • Increasing Laser Hair Treatment and OTC Drugs

Opportunities

  • Rising consumer concern pertaining to receding hairlines

Challenges

  • Lack of proper treatment and the shortage of R&D in emerging economies

Competitive Landscape:

Some of the key players profiled in the report are Procter & Gamble (United States), L’Oreal (France), Unilever (United Kingdom), Taisho (Japan), Henkel (Germany), Merck & Co. (United States), Shiseido (Japan), Johnson & Johnson Consumer Inc. (United States), Rohto (Japan), Lifes2Good (Ireland), Gerolymatos International (Greece) and Toppik Inc. (United States).

Additionally, the following companies can also be profiled that are part of our coverage like Nanogen (United Kingdom), Oxford BioLabs Ltd. (United Kingdom) and Ultrax Labs (United States).

AMA Research sees the United States and United Kingdom Players retain a maximum share of the Global Hair Loss Men and Women market by 2026. Considering Market by End-Use, the sub-segment i.e. Dermatology clinics will boost the Hair Loss Men and Women market.

Considering Market by Sales Channel, the sub-segment i.e. Prescription will boost the Hair Loss Men and Women market.

What Can be Explored with the Hair Loss Men and Women Market Study

 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Hair Loss Men and Women Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Hair Loss Men and Women
 Understand the Competitive Scenario
– Track Right Markets
– Identify the Right Verticals

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Hair Loss Men and Women market.

In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Hair Loss Men and Women market.

In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.

Finally, the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment.

This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.

Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that include Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Hair Loss Men and Women Comprehensive Study

Source

Recent Posts

Alopecia Clinical Trials Review

Alopecia Clinical Trials Review

Global Alopecia Clinical Trials Review

The “Alopecia – Global Clinical Trials Review, H2, 2021” clinical trials have been added to the ResearchAndMarkets offering.

The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on a number of ongoing trials).

The report enhances the decision-making capabilities and helps to create an effective counter-strategies to gain a competitive advantage.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with the reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to Buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Key Topics Covered:

  • Report Guidance
  • The Publisher’s Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Alopecia to Dermatology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Alopecia to Dermatology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Alopecia Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profile Snapshots
  • Appendix

Companies Mentioned

  • Pfizer Inc
  • Concert Pharmaceuticals Inc
  • Johnson & Johnson
  • AbbVie Inc
  • Aclaris Therapeutics Inc
  • Cosmo Pharmaceuticals NV
  • Dr. Reddy’s Laboratories Ltd
  • Almirall SA
  • Applied Biology Inc
  • GlaxoSmithKline Plc

For more information about this clinical trials report visit https://www.researchandmarkets.com

Global Alopecia Clinical Trials Review

Source

Recent Posts

Platelet Rich Plasma and Stem Cell Alopecia

Platelet Rich Plasma and Stem Cell Alopecia

Platelet Rich Plasma and Stem Cell Alopecia Treatment Market

The Global Platelet Rich Plasma and Stem Cell Alopecia Treatment market exposition comprehensive information that help to build business strategists during the forecast 2021-2027.

Which provides an exhaustive analysis of key market trends & dynamics along with market estimates & forecasts covering major geographies/countries on the basis of historical data. Considering Platelet Rich Plasma and Stem Cell Alopecia Treatment revolutions of the cat1 industry which is major factors of growth.

Research Methodology

Our research methodology constitutes a mix of secondary & primary research sources which ideally starts from exhaustive data mining, conducting primary interviews (suppliers/distributors/end-users), and formulating insights, estimates, growth rates accordingly. Final primary validation is a mandate to confirm our research findings with Key Opinion Leaders (KoLs), Industry Experts, Self-Adhesive Labels includes major supplies & Independent Consultants among others.

The report used two methodologies FPNV Positioning Matrix and the Competitive Strategic Window to assess the figures for all segments and competitive marketplace in terms of product satisfaction and business strategy they follow to sustain in the market.

Pharmaceuticals and Healthcare Development

– India has reached out to top American pharma companies seeking investment in the country’s pharmaceutical and medical devices sector
– The Serum Institute of India will invest 240 million pounds in the UK
– The annual change in WPI notified by the government works out to 0.5% for 2020, the drug prices regulator National Pharmaceutical Pricing Authority said.

Market Segmentation

The Platelet Rich Plasma and Stem Cell Alopecia Treatment market is segmented on the basis of type, application, end-use industry, and region & country.

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market by Type

Based on Platelet Rich Plasma and Stem Cell Alopecia Treatment type, the market is divided into type Androgenic Alopecia, Congenital Alopecia, Cicatricial Or Scarring Alopecia. Platelet Rich Plasma and Stem Cell Alopecia Treatment market’s sub-segment is expected to hold the largest market share during the forecast period. Increased demand for high-quality industrial valves in the Pharmaceuticals and Healthcare and other industries.

Also to mitigate the risk of contamination is driving the demand for Platelet Rich Plasma and Stem Cell Alopecia Treatment at present. The growing concern about the market and industry is expected to boost the Platelet Rich Plasma and Stem Cell Alopecia Treatment market in Pharmaceuticals and Healthcare.

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market by Application

Based on Platelet Rich Plasma and Stem Cell Alopecia Treatment application, the market is divided into Hospital, Dermatology Clinic, Other. Platelet Rich Plasma and Stem Cell Alopecia Treatment application valves are one of the most basic and indispensable components of today’s modern technological society. A market segment is expected to hold the largest market share in the global Platelet Rich Plasma and Stem Cell Alopecia Treatment market.

Global Market Scope and Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size

The scope of the report is to provide a 360-degree view of the market by assessing the entire value chain and analyzing the key Platelet Rich Plasma and Stem Cell Alopecia Treatment market trends from 2021 to 2027 underlying in specific geographies. Qualitative and quantitative aspects are interlinked to provide rationales on market numbers, CAGR, and forecasts.

Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Country Level Analysis

Most of the countries are estimated to emerge as the fastest growing region and hold the largest market share in the global industrial Platelet Rich Plasma and Stem Cell Alopecia Treatment market, mainly due to Growing industry trends of present situations, which cannot be ignored. Geographically, regional insights have been segmented on the basis of North America, Europe, Asia Pacific, South America and The Middle East And Africa region.

Key Platelet Rich Plasma and Stem Cell Alopecia Treatment market players identified in the report are listed below

Kerastem, Stemcell Technologies, Eclipse, Glofinn Oy., Regen Lab SA, Histogen, RepliCel Life Sciences

Market

Some of the other major highlights of the demand for Platelet Rich Plasma and Stem Cell Alopecia Treatment report include analysis, purchasing volume, prices, pricing analysis, and regulatory framework. Coverage on manufacturing structure, distribution channels, and Porter’s Five Forces analysis are also incorporated in the scope to provide analysis on the demand and supply side. This is anticipated to create opportunities for the growth of the Platelet Rich Plasma and Stem Cell Alopecia Treatment market during the forecast period.

COVID-19 Impact Analysis

– The COVID-19 pandemic had a significant impact on the on-trade segment and Industry.
– Manufacturers are comprehending strategies to revive from the current situation by means of reshaping their sales channels as well as product innovation.
– The duration of the virus outbreak remains a key factor in assessing the overall impact of the pandemic. However, the global Platelet Rich Plasma and Stem Cell Alopecia Treatment industry is expected to stabilize after 2021.
– The liquor industry was not impacted severely due to the pandemic.

Key Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Trends

– The report identifies, determines, and forecasts the Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market segments based on their type, sub-type, technology used, applications, end-users, and regions.
– Industry to Industry Holds Largest Share in the Platelet Rich Plasma and Stem Cell Alopecia Treatment Market
– It examines the micro-markets based on their growth trends, development patterns, future prospects, and contribution to the overall market.
– Demand from Regional / geographical is Expected to Drive the Growth
– Rising Adoption of Market Segments in the Platelet Rich Plasma and Stem Cell Alopecia Treatment Growth
– North American, Europe is Expected to Witness Higher Growth Rate over the Forecast Period
– It studies the competitive developments such as partnerships and collaborations, mergers and acquisitions (M&A), research and development (R&D) activities, product developments, and expansions in the Global Platelet

Rich Plasma and Stem Cell Alopecia Treatment Market.

Table of Contents

Study Coverage: It includes key manufacturers covered, key market segments, the scope of products offered in the global Platelet Rich Plasma and Stem Cell Alopecia Treatment market, years considered, and study objectives. Additionally, it touches on the segmentation study provided in the report on the basis of the type of product and application.

Executive Summary: It gives a summary of key studies, market growth rate, competitive landscape, market drivers, trends, and issues, and macroscopic indicators.

Production by Region: Here, the report provides information related to import and export, production, revenue, and key players of all regional markets studied.

Profile of Manufacturers: Each player profiled in this section is studied on the basis of SWOT analysis, their products, production, value, capacity, and other vital factors.

Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Growth are segmented on the basis of market type, application, end-user and region.

Based on Type

Androgenic Alopecia
Congenital Alopecia
Cicatricial Or Scarring Alopecia

Based on Application

Hospital
Dermatology Clinic
Other

Regions Covered

Americas
North America
United States
Canada
Mexico
South America
Brazil
Argentina
Chile
Colombia
Rest Of Latin America

Europe
United Kingdom
Germany
France
Italy
Spain
Netherlands
Sweden
Rest of Europe

Asia-Pacific
China
India
Japan
South Korea
Australia
Singapore
Indonesia
Malaysia
Thailand
Philippines,
Vietnam
Rest of Asia-Pacific

The Middle East And Africa
Saudi Arabia
United Arab Emirates
South Africa
Iran
Turkey
Morocco
Nigeria
Algeria
Cameroon
Chad
Congo
Egypt
Kuwait
Rest of LAMEA

Platelet Rich Plasma and Stem Cell Alopecia Treatment Market

Source

Recent Posts

Celluma RESTORE for Hair Loss

Celluma RESTORE for Hair Loss

BioPhotas Announces Celluma RESTORE for Hair Loss

BioPhotas, Inc., the market leader in therapeutic LED Light Therapy devices announced today a major product line extension to the Company’s award-winning Celluma SERIES of Light Therapy Devices.

The all-in-one Celluma RESTORE is the first LED device FDA-cleared for over-the-counter (OTC) use to treat three common concerns of the mature individual in a single device: hair loss, ageing skin, and general pain conditions. This is the 14th model in the Celluma SERIES.

The all-in-one Celluma RESTORE is the first LED device FDA-cleared for over-the-counter (OTC) use to treat three common concerns of the mature individual in a single device: hair loss, ageing skin, and general pain conditions.

Commenting on the latest addition to the product line, BioPhotas President and Chief Executive Officer Patrick Johnson said, “It’s great to add a Hair Restoration indication-for-use to our long list of treatment clearances from the FDA. Providing a single device that treats whole body aches and pains, fine lines and wrinkles, and hair loss on the scalp is the ultimate baby-boomer anti-ageing device.

Now the mature individual interested in feeling and looking great, and retaining their youthful appearance, can have a device at home that meets all of their rejuvenating needs.” The Celluma RESTORE is targeted directly at the multi-billion-dollar global health and wellness market, specifically, the non-invasive hair restoration segment of the medical aesthetics industry.

The Celluma RESTORE is non-toxic, non-invasive, and painless. The device is versatile, convenient, and easy-to-use in both a clinical setting or at home. Celluma’s patented, the shape-taking design permits customized placement over the head to effectively deliver light energy and promote hair regrowth.

Additionally, the Celluma RESTORE can be placed anywhere on the body to reduce pain and improve skin health. Measuring 16″ x 8″ overall with a treatment area of 14″ x 6″, the Celluma RESTORE can be stored flat in a drawer for convenience and easy access.

Commenting further on the announcement, Mr Johnson said, “Having just celebrated the 10th anniversary of BioPhotas, it is only appropriate that we receive our 10th indication-for-use clearance from the FDA. The Celluma SERIES now has more regulatory credentials than any other LED device in the world and is legally registered for sale in 78 countries around the globe.

We anticipate that the new RESTORE will be available to our U.S. customers in mid-August. The new device is already slated for MDR Tech File review later this summer and should be available in the E.U. and U.K. in the 4th quarter.”

The Celluma SERIES has also continued its winning ways by adding five new industry awards in the first half of 2021. Celluma Light Therapy was recognized by Les Nouvelles Esthetiques & Spa Magazine with two Best Product awards. Dermascope Magazine also recognized Celluma devices with two Aesthetician’s Choice Awards. And the readers of Skin Deep Magazine awarded Celluma the Reader’s Choice award for Favorite LED Device, making the Celluma SERIES the most award-winning LED device with more than 40 international awards.

Visit www.celluma.com to see the complete line of Celluma devices.

About BioPhotas, Inc.

In providing unique devices founded on NASA-developed technology and backed by clinical studies, BioPhotas is bringing to market safe, effective and affordable devices that unlock the clinical power of biophotonics. BioPhotas develops and markets devices for healthcare providers and consumers that conveniently treat a variety of skin, muscle and joint conditions.

BioPhotas Announces Celluma RESTORE for Hair Loss

Source

Recent Posts

Androgenic Alopecia Drug Market

Androgenic Alopecia Drug Market

Androgenic Alopecia Drug Market Size and Industry Analysis Report, by Type, by Application, by Country & Region, and Segment Forecasts, 2016 – 2027

Androgenic Alopecia Drug Market Size and Forecasts 2021 to 2027

The Global Androgenic Alopecia Drug Market witnessed a rapid growth in the historic period from 2016 to 2019 and is anticipated to witness significant growth during the forecast period.

Global Androgenic Alopecia Drug Market Size, Trends, Growth, Competitive Landscape and Key Regional Analysis to 2027” offers broad information and understanding of the Androgenic Alopecia Drug markets. The report analyses the Androgenic Alopecia Drug market for the historical (2016–2020) and forecast (2021–2027) periods. The report includes drivers, restraints and opportunities influencing the market, market size analysis with respect to revenue.

The report also provides a snapshot of the competitive landscape of the key players operating in the market along with the percentage market share of the top players. The report has a section on the impact of COVID-19 on the Androgenic Alopecia Drug market at the global and country levels.

This analysis includes demand & supply-side implications of the Androgenic Alopecia Drug market in 2019. The report is built using data and information sourced from primary & secondary research, proprietary databases paid database among others.

Androgenic Alopecia Drug Market Snapshot

Scope of the Androgenic Alopecia Drug Market Report:

This report provides an in-depth analysis of the Global Androgenic Alopecia Drug Market. The market estimates and forecasts provided in the research report are the results of in-depth secondary research coupled with primary interviews and in-house expert opinions. These market estimates and forecasts have been considered by reviewing the impact of various political, social, and economic factors along with the current market scenarios affecting the Androgenic Alopecia Drug market growth

Along with the Androgenic Alopecia Drug market summary, which includes the market dynamics comprising of drivers, restraints, and opportunities the chapter also includes a Porter’s Five Forces analysis which explains: the threat of new entrants, buyers bargaining power, bargaining power of supplier, the threat of substitutes, and competitive rivalry in the Global Androgenic Alopecia Drug Market. Furthermore, the supply chain analysis explains the various participants, such as raw material suppliers, system integrators, distributors, intermediaries and end-users within the ecosystem of the Androgenic Alopecia Drug market. It provides vendor landscape at the global level and summary of the key upcoming projects/ products

Segments Covered in the Androgenic Alopecia Drug Market Report:

This report forecasts revenue growth at global, regional, and country levels and offers an analysis of latest industry developments in each of the sub-segments from 2016 to 2027.

Global Androgenic Alopecia Drug Market, By Product

  • RK-023
  • Refagro
  • RCH-01
  • SM-04554
  • HYG-440
  • Others

Global Androgenic Alopecia Drug Market, By Application

  • Clinic
  • Hospital
  • Home Use

Androgenic Alopecia Drug Market Regional Overview:

The report offers in-depth analysis of the Androgenic Alopecia Drug market at the global, regional (North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa) and key country (the US, Canada, China, India, Japan, South Korea, the U.K., Germany, France, Brazil, Mexico) levels. The market estimates and forecasts for the segmentation mentioned in the study will be provided at regional and country level. The market estimates and forecast will help understand the dominant region in 2020 and will further enlighten the upcoming region that will generate major revenue in the Androgenic Alopecia Drug market.

Global Androgenic Alopecia Drug Market: Competitive Landscape

The market analysis includes a chapter solely dedicated for key players operating in the Global Androgenic Alopecia Drug Market wherein the analysis provide an insight of the business overview, financial statements, product overview, and the strategic initiatives adopted by the market players. The companies mentioned in the study can be customized according to the client’s requirements.

Global Androgenic Alopecia Drug Market, Key Players

  • Allergan, Inc.
  • Histogen, Inc.
  • R-Tech Ueno, Ltd.
  • Hygeia Therapeutics, Inc.
  • SWITCH Biotech LLC
  • Polichem S.A.
  • Kasiak Research Pvt. Ltd.

Key Questions Addressed:

  • Which innovative technology trends are expected over the next seven years?
  • Which sub segment is likely to get the maximum opportunity to grow during the forecast period?
  • Which region is projected to lead with the highest market share by 2027?
  • How are companies instigating organic and inorganic strategies to gain a surge in the market share?

Global Androgenic Alopecia Drug Market: Research Methodology

The research methodology is a mix of primary research, secondary research and industry opinion leaders. Moreover, secondary research comprises of sources such as company annual reports, press releases, and research papers related to the industry. Other sources include government websites, trade journals and associations are also been reviewed for developing business growth strategies in Androgenic Alopecia Drug Market.

Androgenic Alopecia Drug Market Size and Industry Analysis Report, by Type, by Application, by Country & Region, and Segment Forecasts, 2016 – 2027

Source

Recent Posts

Gene Tied to Balding

Gene Tied to Balding

Gene Tied to Balding May Also Raise COVID Risks for Men

It’s long been known that COVID-19 is more fatal for men than women, and new research links some of that excess risk to a gene known to cause a form of hair loss in males.

A U.S. team of researchers first suspected the link when they noticed that men with a common form of hormone-sensitive hair loss, known as androgenetic alopecia, were also more prone to being hospitalized with COVID-19.

“Among hospitalized men with COVID-19, 79% presented with androgenetic alopecia compared to 31%-53% that would be expected in a similarly aged match population,” said researchers led by Dr Andy Goren, chief medical officer at Applied Biology Inc. in Irvine, Calif. They presented their findings May 6 at the virtual spring meeting of the European Academy of Dermatology and Venereology (EADV).

The researchers noted that androgenetic alopecia is caused by the activity of the androgen receptor (AR) gene, which in some men can lead to hair loss. An enzyme called TMPRSS2, the key to COVID-19 infection, is also androgen-sensitive, and might be affected by the AR gene as well, Goren’s group explained.

One key segment on the AR gene appears to affect both COVID-19 severity and the propensity of men to lose their hair due to androgenetic alopecia.

In the new study, the Irvine group conducted a genetic analysis of 65 men hospitalized with COVID-19. They found that men with certain structural differences in the AR gene were more likely to develop severe COVID-19. Speaking in a meeting press release, Goren said the AR gene aberration “could be used as a biomarker to help identify male COVID-19 patients most at risk for ICU admissions.”

He also believes that “the identification of a biomarker connected with the androgen receptor is another piece of evidence highlighting the important role of androgens [male hormones] in COVID-19 disease severity.”

Dr. Teresa Murray Amato is chair of emergency medicine at Long Island Jewish Forest Hills in New York City and has seen many severe cases of COVID-19. She wasn’t connected to the new research, but said it “did show a significant correlation between a higher number of androgen receptors and a higher incidence of ICU admissions for patients infected with COVID-19.”

Amato added, “While the study is small and the exact association is not completely understood, it may show at least one answer to why men were more likely to be admitted to ICU and have overall higher morality with COVID-19 infections.”

According to Amato, more research is needed to determine whether “medications that block androgen receptors will be useful in treating a subset of [COVID-19] patients.”

Because the findings were presented at a medical meeting, they should be considered preliminary until published in a peer-reviewed journal.

Gene Tied to Balding May Also Raise COVID Risks for Men

Source

Recent Posts